References
- MitchellJDBorasioGDAmyotrophic lateral sclerosisLancet200736995782031204117574095
- StrongMJAbrahamsSGoldsteinLHAmyotrophic lateral sclerosis – frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteriaAmyotroph Lateral Scler Frontotemporal Degener2017183–415317428054827
- TraynorBJAlexanderMCorrBFrostEHardimanOEffect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996–2000J Neurol Neurosurg Psychiatry20037491258126112933930
- JawaidAMurthySBWilsonAMA decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALSAmyotrophic Lateral Sclerosis201011654254820500116
- MarinBDesportJCKajeuPAlteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patientsJ Neurol Neurosurg Psychiatry201182662863421097551
- GentonLViatteVJanssensJPHeritierACPichardCNutritional state, energy intakes and energy expenditure of amyotrophic lateral sclerosis (ALS) patientsClin Nutr201130555355921798636
- PaganoniSDengJJaffaMCudkowiczMEWillsAMBody mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosisMuscle Nerve2011441202421607987
- MillerRGJacksonCEKasarskisEJPractice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioural impairment (an evidence-based review)Neurology2009731227123319822873
- AhmedRMCagaJDevenneyECognition and eating behavior in amyotrophic lateral sclerosis: effect on survivalJ Neurol201626381593160327260291
- CastonguayTWApplegateEAUptonDESternJSHunger and appetite: old concepts/new distinctionsNutr Rev19834141011106346147
- HolmTMaierAWicksPSevere loss of appetite in amyotrophic lateral sclerosis patients: online self-assessment studyInteract J Med Res201321e823608722
- RobbinsJSwallowing in ALS and motor neuron disordersNeurol Clin19875221322911681400
- NeudertCOliverDWasnerMBorasioGDThe course of the terminal phase in patients with amyotrophic lateral sclerosisJ Neurol200124861261611518004
- MuscaritoliMKushtaIMolfinoAInghilleriMSabatelliMRossi FanelliFNutritional and metabolic support in patients with amyotrophic lateral sclerosisNutrition2012281095996622677356
- KornerSHendricksMKolleweKWeight loss, dysphagia and supplement intake in patients with amyotrophic lateral sclerosis (ALS): impact on quality of life and therapeutic optionsBMC Neurol2013131848423848967
- HeffernanCJenkinsonCHolmesTNutritional management in MND/ALS patients: an evidence based reviewAmyotroph Lateral Scler Other Motor Neuron Disord200452728315204009
- SilaniVKasarskisEJYanagisawaNNutritional management in amyotrophic lateral sclerosis: a worldwide perspectiveJ Neurol1998245Suppl 2S13S19 discussion S299747929
- GreenwoodDINutrition management of amyotrophic lateral sclerosisNutr Clin Pract201328339239923466470
- AndersenPMBorasioGDDenglerRGood practice in the management of amyotrophic lateral sclerosis: clinical guidelines. An evidence-based review with good practice points. EALSC Working GroupAmyotroph Lateral Scler20078419521317653917
- ToepferCFAKRLMGastrointestinal dysfunction in amyotrophic lateral sclerosisAmyotrophic Lateral Scler Other Motor Neuron Disord2009111519
- NgoSTSteynFJHuangLAltered expression of metabolic proteins and adipokines in patients with amyotrophic lateral sclerosisJ Neurol Sci20153571–2222726198021
- ChaudhriOSmallCBloomSGastrointestinal hormones regulating appetitePhilos Trans R Soc Lond B Biol Sci200636114711187120916815798
- AndrewsZBAbizaidANeuroendocrine mechanisms that connect feeding behavior and stressFront Neurosci2014831225324716
- AhmedRMIrishMPiguetOAmyotrophic lateral sclerosis and frontotemporal dementia: distinct and overlapping changes in eating behaviour and metabolismLancet Neurol201615333234226822748
- VercruyssePSinnigerJEl OussiniHAlterations in the hypothalamic melanocortin pathway in amyotrophic lateral sclerosisBrain2016139Pt 41106112226984187
- CykowskiMDTakeiHSchulzPEAppelSHPowellSZTDP-43 pathology in the basal forebrain and hypothalamus of patients with amyotrophic lateral sclerosisActa Neuropathol Commun2014217125539830
- KasarskisEJBerrymanSVanderleestJGSchneiderARMcClainCJNutritional status of patients with amyotrophic lateral sclerosis: relation to the proximity of deathAm J Clin Nutr19966311301378604660
- DesportJCPreuxPMMagyLFactors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis.(Brief Article)Am J Clin Nutr200174332811522556
- IoannidesZANgoSTHendersonRDMcCombePASteynFJAltered metabolic homeostasis in amyotrophic lateral sclerosis: mechanisms of energy imbalance and contribution to disease progressionNeurodegener Dis2016165–638239727400276
- BouteloupCDesportJCClavelouPHypermetabolism in ALS patients: an early and persistent phenomenonJ Neurol200925681236124219306035
- FrostJOkunSVaughanTHeywoodJWicksPPatient-reported outcomes as a source of evidence in off-label prescribing: analysis of data from PatientsLikeMeJ Med Internet Res2011131e621252034
- BradleyWGAndersonFGowdaNMillerRGGroup ACSChanges in the management of ALS since the publication of the AAN ALS practice parameter 1999Amyotroph Lateral Scler Other Motor Neuron Disord20045424024415799554
- SalvioniCCStanichPAlmeidaCSOliveiraASNutritional care in motor neurone disease/amyotrophic lateral sclerosisArq Neuropsiquiatr201472215716324604371
- SpataroRFicanoLPiccoliFLa BellaVPercutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: effect on survivalJ Neurol Sci20113041–2444821371720
- FasanoAFiniNFerraroDPercutaneous endoscopic gastrostomy, body weight loss and survival in amyotrophic lateral sclerosis: a population-based registry studyAmyotroph Lateral Scler Frontotemporal Degener2017110
- MockfordCJenkinsonCFitzpatrickRA review: carers, MND and service provisionAmyotroph Lateral Scler20067313214116963402
- MNDAEating and drinking with motor neurone disease (MND)2017 Available from: https://www.mndassociation.org/wp-content/uploads/Eating-and-drinking-with-MND-final-web-PDF-2017.pdfAccessed June 16, 2017
- RioACawadiasENutritional advice and treatment by dietitians to patients with amyotrophic lateral sclerosis/motor neurone disease: a survey of current practice in England, Wales, Northern Ireland and CanadaJ Hum Nutr Diet200720131317241187
- KasarskisEJMendiondoMSMatthewsDEEstimating daily energy expenditure in individuals with amyotrophic lateral sclerosisAm J Clin Nutr201499479280324522445
- ProGas StudyGGastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort studyLancet Neurol201514770270926027943
- Rahnemai-AzarAARahnemaiazarAANaghshizadianRKurtzAFarkasDTPercutaneous endoscopic gastrostomy: indications, technique, complications and managementWorld J Gastroenterol201420247739775124976711
- StavroulakisTWalshTShawPJMcDermottCJProgasSGastrostomy use in motor neurone disease (MND): a review, meta-analysis and survey of current practiceAmyotroph Lateral Scler Frontotemporal Degener20131429610422985431
- WillsA-MHubbardJMacklinEAHypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trialLancet201438399342065207224582471
- MattsonMPCutlerRGCamandolaSEnergy intake and amyotrophic lateral sclerosisNeuromolecular Med200791172017114821
- SilvaLBdCMourãoLFSilvaAAEffect of nutritional supplementation with milk whey proteins in amyotrophic lateral sclerosis patientsArquivos de Neuro-Psiquiatria20106826326820464297
- DorstJCypionkaJLudolphACHigh-caloric food supplements in the treatment of amyotrophic lateral sclerosis: a prospective interventional studyAmyotroph Lateral Scler Frontotemporal Degener2013147–853353623944684
- ThomasBFElSohlyMAChapter 1 – The botany of Cannabis sativa LThe Analytical Chemistry of CannabisElsevier2016126
- Di MarzoVBifulcoMDe PetrocellisLThe endocannabinoid system and its therapeutic exploitationNat Rev Drug Discov20043977178415340387
- GrotenhermenFMuller-VahlKThe therapeutic potential of cannabis and cannabinoidsDtsch Arztebl Int201210929–3049550123008748
- AlexanderSPTherapeutic potential of cannabis-related drugsProg Neuropsychopharmacol Biol Psychiatry20166415716626216862
- AmtmannDWeydtPJohnsonKLJensenMPCarterGTSurvey of cannabis use in patients with amyotrophic lateral sclerosisAm J Hosp Palliat Care20042129510415055508
- CarterGTAboodMEAggarwalSKWeissMDCannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trialsAm J Hosp Palliat Care201027534735620439484
- CowleyMASmartJLRubinsteinMLeptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleusNature2001411683648048411373681
- KochMVarelaLKimJGHypothalamic POMC neurons promote cannabinoid-induced feedingNature20155197541455025707796
- KalraSPHorvathTLNeuroendocrine interactions between galanin, opioids, and neuropeptide Y in the control of reproduction and appetiteAnn N Y Acad Sci19988632362409928174
- ManfrediGXuZMitochondrial dysfunction and its role in motor neuron degeneration in ALSMitochondrion200552778716050975
- CozzolinoMCarriMTMitochondrial dysfunction in ALSProg Neurobiol2012972546621827820
- MuydermanHChenTMitochondrial dysfunction in amyotrophic lateral sclerosis – a valid pharmacological target?Br J Pharmacol201417182191220524148000
- VolkowNDBalerRDComptonWMWeissSRAdverse health effects of marijuana useN Engl J Med2014370232219222724897085
- WrenAMSealLJCohenMAGhrelin enhances appetite and increases food intake in humansJ Clin Endocrinol Metab20018612599211739476
- CzellDBaldingerRSchneiderUNeuwirthCWeberMThe role of the SenseWear device and ghrelin for metabolism in amyotrophic lateral sclerosisAmyotroph Lateral Scler Frontotemporal Degener2016173–4295296
- LimELeeSLiEKimYParkSGhrelin protects spinal cord motoneurons against chronic glutamate-induced excitotoxicity via ERK1/2 and phosphatidylinositol-3-kinase/Akt/glycogen synthase kinase-3beta pathwaysExp Neurol2011230111412221530509
- LeeSKimYLiEParkSGhrelin protects spinal cord motoneurons against chronic glutamate excitotoxicity by inhibiting microglial activationKorean J Physiol Pharmacol2012161434822416219
- ColldénGTschopMHMullerTDTherapeutic potential of targeting the ghrelin pathwayInt J Mol Sci2017184E79828398233
- XuHHuangXRiserusUDietary fiber, kidney function, inflammation, and mortality riskClin J Am Soc Nephrol20149122104211025280496
- YoungRPHopkinsRJHigh dietary fiber lowers systemic inflammation: potential utility in COPD and lung cancerAm J Med20141278e13
- SlavinJFiber and prebiotics: mechanisms and health benefitsNutrients2013541417143523609775
- FondellEO’ReillyEJFitzgeraldKCDietary fiber and amyotrophic lateral sclerosis: results from 5 large cohort studiesAm J Epidemiol2014179121442144924816788
- NievesJWGenningsCFactor-LitvakPAssociation between dietary intake and function in amyotrophic lateral sclerosisJAMA Neurol201673121425143227775751
- HanischFSkudlarekABerndtJKornhuberMECharacteristics of pain in amyotrophic lateral sclerosisBrain Behav201553e0029625642388
- LayzerRBDiagnostic implications of clinical fasciculation and crampsAdv Neurol19823623297180684
- GubbaySSKahanaEZilberNCooperGPintovSLeibowitzYAmyotrophic lateral sclerosis. A study of its presentation and prognosisJ Neurol198523252953004056836
- LayzerRBThe origin of muscle fasciculations and crampsMuscle Nerve19941711124312497935546
- BaldisseraFCavallariPDworzakFMotor neuron ‘bistability’. A pathogenetic mechanism for cramps and myokymiaBrain1994117Pt 59299397953602
- ObiTMizoguchiKMatsuokaHTakatsuMNishimuraYMuscle cramp as the result of impaired GABA function–an electrophysiological and pharmacological observationMuscle Nerve19931611122812318413375
- MillerRGJacksonCEKasarskisEJQuality Standards Subcommittee of the American Academy of NeurologyPractice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of NeurologyNeurology200973151227123319822873
- AchanJTalisunaAOErhartAQuinine, an old anti-malarial drug in a modern world: role in the treatment of malariaMalar J20111014421609473
- Man-Son-HingMWellsGLauAQuinine for nocturnal leg cramps: a meta-analysis including unpublished dataJ Gen Intern Med19981396006069754515
- DysonEHProudfootATPrescottLFHeyworthRDeath and blindness due to overdose of quinineBr Med J (Clin Res Ed)198529164873133
- TuckerJMTownsendDMAlpha-tocopherol: roles in prevention and therapy of human diseaseBiomed Pharmacother200559738038716081238
- AyresSJrMihanRLeg cramps (systremma) and “restless legs” syndrome. Response to vitamin E (tocopherol)Calif Med1969111287915346435
- Michal FreedmanDKunclRWWeinsteinSJMalilaNVirtamoJAlbanesDVitamin E serum levels and controlled supplementation and risk of amyotrophic lateral sclerosisAmyotroph Lateral Scler Frontotemporal Degener201314424625123286756
- de BustosFJimenez-JimenezFJMolinaJACerebrospinal fluid levels of alpha-tocopherol in amyotrophic lateral sclerosisJ Neural Transm (Vienna)19981056–77037089826112
- IwasakiYIkedaKKinoshitaMVitamin A and E levels are normal in amyotrophic lateral sclerosisJ Neurol Sci199513221931948543947
- WangHO’ReillyEJWeisskopfMGVitamin E intake and risk of amyotrophic lateral sclerosis: a pooled analysis of data from 5 prospective cohort studiesAm J Epidemiol2011173659560221335424
- VeldinkJHKalmijnSGroeneveldGJIntake of polyunsaturated fatty acids and vitamin E reduces the risk of developing amyotrophic lateral sclerosisJ Neurol Neurosurg Psychiatry200778436737116648143
- AscherioAWeisskopfMGO’ReillyEJVitamin E intake and risk of amyotrophic lateral sclerosisAnn Neurol200557110411015529299
- KwiecinskiHJanikPJamrozikZOpuchlikAThe effect of selegiline and vitamin E in the treatment of ALS: an open randomized clinical trialsNeurol Neurochir Pol2001351 Suppl101106
- DesnuelleCDibMGarrelCFavierAA double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study GroupAmyotroph Lateral Scler Other Motor Neuron Disord20012191811465936
- GalbusseraATremolizzoLBrighinaLVitamin E intake and quality of life in amyotrophic lateral sclerosis patients: a follow-up case series studyNeurol Sci200627319019316897634
- GrafMEckerDHorowskiRHigh dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind studyJ Neural Transm (Vienna)2005112564966015517433
- DurlachJBacPBaraMGuiet-BaraAPhysiopathology of symptomatic and latent forms of central nervous hyperexcitability due to magnesium deficiency: a current general schemeMagnes Res200013429330211153899
- SeboPCeruttiBHallerDMEffect of magnesium therapy on nocturnal leg cramps: a systematic review of randomized controlled trials with meta-analysis using simulationsFam Pract201431171924280947
- FondellEO’ReillyEJFitzgeraldKCMagnesium intake and risk of amyotrophic lateral sclerosis: results from five large cohort studiesAmyotroph Lateral Scler Frontotemporal Degener2013145–635636123777266
- LongneckerMPKamelFUmbachDMDietary intake of calcium, magnesium and antioxidants in relation to risk of amyotrophic lateral sclerosisNeuroepidemiology200019421021610859501
- ChangEGhoshNYanniDLeeSAlexandruDMozaffarTA review of spasticity treatments: pharmacological and interventional approachesCrit Rev Phys Rehabil Med2013251–2112225750484
- KhederANairKPSpasticity: pathophysiology, evaluation and managementPract Neurol201212528929822976059
- SimonOYelnikAPManaging spasticity with drugsEur J Phys Rehabil Med201046340141020927006
- MaherTJWurtmanRJl-threonine administration increases glycine concentrations in the rat central nervous systemLife Sci19802616128312866770208
- TestaDCaraceniTFetoniVGirottiFChronic treatment with l-threonine in amyotrophic lateral sclerosis: a pilot studyClin Neurol Neurosurg1992941791353011
- LeeAPattersonVA double-blind study of l-threonine in patients with spinal spasticityActa Neurol Scand19938853343388296531
- BlinOPougetJAubrespyGGueltonCCrevatASerratriceGA double-blind placebo-controlled trial of L-threonine in amyotrophic lateral sclerosisJ Neurol1992239279811313078
- NgLKhanFYoungCAGaleaMSymptomatic treatments for amyotrophic lateral sclerosis/motor neuron diseaseCochrane Database Syst Rev20171CD01177628072907
- PetroDJEllenbergerCJrTreatment of human spasticity with delta 9-tetrahydrocannabinolJ Clin Pharmacol1981218–9 Suppl413S416S6271839
- PryceGBakerDEndocannabinoids in multiple sclerosis and amyotrophic lateral sclerosisHandb Exp Pharmacol201523121323126408162
- FlacheneckerPHenzeTZettlUKNabiximols (THC/CBD oromucosal spray, Sativex(R)) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticityEur Neurol2014715–627127924525548
- FernandezOAdvances in the management of MS spasticity: recent observational studiesEur Neurol201472Suppl 1121425278118
- BilslandLGDickJRPryceGIncreasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 miceFASEB J20062071003100516571781
- ShoemakerJLSeelyKAReedRLCrowJPPratherPLThe CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onsetJ Neurochem20071011879817241118
- RossiSDe ChiaraVMusellaAAbnormal sensitivity of cannabinoid CB1 receptors in the striatum of mice with experimental amyotrophic lateral sclerosisAmyotroph Lateral Scler2010111–2839019452308
- WeberMGoldmanBTrunigerSTetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trialJ Neurol Neurosurg Psychiatry201081101135114020498181
- Group ALALSUntangled No. 16: cannabisAmyotroph Lateral Scler201213440040422632446
- NehligADavalJLDebryGCaffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effectsBrain Res Brain Res Rev19921721391701356551
- PotenzaRLArmidaMFerranteAEffects of chronic caffeine intake in a mouse model of amyotrophic lateral sclerosisJ Neurosci Res201391458559223361938
- FondellEO’ReillyEIFitzgeraldKCIntakes of caffeine, coffee and tea and risk of amyotrophic lateral sclerosis: results from five cohort studiesAmyotroph Lateral Scler Frontotemporal Degener2015165–636637125822002
- BeghiEPupilloEMessinaPCoffee and amyotrophic lateral sclerosis: a possible preventive roleAm J Epidemiol201117491002100821946385
- Onatibia-AstibiaAFrancoRMartinez-PinillaEHealth benefits of methylxanthines in neurodegenerative diseasesMol Nutr Food Res2017
- YenisettiSCManjunathMJMuralidharaCNeuropharmacological properties of Withania somnifera – Indian Ginseng: an overview on experimental evidence with emphasis on clinical trials and patentsRecent Pat CNS Drug Discov201610220421527316579
- KolahdouzanMHamadehMJThe neuroprotective effects of caffeine in neurodegenerative diseasesCNS Neurosci Ther201723427229028317317
- ADBThe ketogenic diet in epilepsyCan Med Assoc J193124110610720318124
- PetermanMGThe ketogenic diet in epilepsyJAMA1925842619791983
- StafstromCERhoJMThe ketogenic diet as a treatment paradigm for diverse neurological disordersFront Pharmacol201235922509165
- GasiorMRogawskiMAHartmanALNeuroprotective and disease-modifying effects of the ketogenic dietBehav Pharmacol2006175–643143916940764
- PaoliABiancoADamianiEBoscoGKetogenic diet in neuromuscular and neurodegenerative diseasesBiomed Res Int2014201447429625101284
- VidaliSAminzadehSLambertBMitochondria: The ketogenic diet–A metabolism-based therapyInt J Biochem Cell Biol201563555925666556
- Echaniz-LagunaAZollJRiberaFMitochondrial respiratory chain function in skeletal muscle of ALS patientsAnn Neurol200252562362712402260
- WiedemannFRWinklerKKuznetsovAVImpairment of mitochondrial function in skeletal muscle of patients with amyotrophic lateral sclerosisJ Neurol Sci1998156165729559989
- VielhaberSWinklerKKirchesEVisualization of defective mitochondrial function in skeletal muscle fibers of patients with sporadic amyotrophic lateral sclerosisJ Neurol Sci19991691–213313910540022
- SicilianoGPastoriniEPasqualiLMancaMLIudiceAMurriLImpaired oxidative metabolism in exercising muscle from ALS patientsJ Neurol Sci20011911–2616511676993
- CrugnolaVLampertiCLucchiniVMitochondrial respiratory chain dysfunction in muscle from patients with amyotrophic lateral sclerosisArch Neurol201067784985420625092
- PalamiucLSchlagowskiANgoSTA metabolic switch toward lipid use in glycolytic muscle is an early pathologic event in a mouse model of amyotrophic lateral sclerosisEMBO Mol Med20157552654625820275
- PradatPFBruneteauGGordonPHImpaired glucose tolerance in patients with amyotrophic lateral sclerosisAmyotroph Lateral Scler2010111–216617120184518
- ZhaoZLangeDJVoustianioukAA ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosisBMC Neurosci200672916584562
- PaoliARubiniAVolekJSGrimaldiKABeyond weight loss: a review of the therapeutic uses of very-low-carbohydrate (ketogenic) dietsEur J Clin Nutr201367878979623801097
- ALS Untangled GroupFournierCBedlackBALS Untangled No. 20: the Deanna protocolAmyotroph Lateral Scler Frontotemporal Degener201314431932323638638
- MoncadaSHiggsAThe L-arginine-nitric oxide pathwayN Engl J Med199332927200220127504210
- AriCPoffAMHeldHEMetabolic therapy with Deanna Protocol supplementation delays disease progression and extends survival in amyotrophic lateral sclerosis (ALS) mouse modelPLoS One201497e10352625061944
- WalkerJBCreatine: biosynthesis, regulation, and functionAdv Enzymol Relat Areas Mol Biol197950177242386719
- CaseyAGreenhaffPLDoes dietary creatine supplementation play a role in skeletal muscle metabolism and performance?Am J Clin Nutr2000722 Suppl607S617S10919967
- O’GormanEBeutnerGWallimannTBrdiczkaDDifferential effects of creatine depletion on the regulation of enzyme activities and on creatine-stimulated mitochondrial respiration in skeletal muscle, heart, and brainBiochim Biophys Acta1996127621611708816948
- StrongMJPatteeGLCreatine and coenzyme Q10 in the treatment of ALSAmyotroph Lateral Scler Other Motor Neuron Disord20001Suppl 4172011466954
- KlivenyiPFerranteRJMatthewsRTNeuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosisNat Med19995334735010086395
- AndreassenOAJenkinsBGDedeogluAIncreases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementationJ Neurochem200177238339011299300
- DeraveWVan Den BoschLLemmensGEijndeBORobberechtWHespelPSkeletal muscle properties in a transgenic mouse model for amyotrophic lateral sclerosis: effects of creatine treatmentNeurobiol Dis200313326427212901841
- MazziniLBalzariniCColomboREffects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary resultsJ Neurol Sci20011911–213914411677005
- RosenfeldJKingRMJacksonCECreatine monohydrate in ALS: Effects on strength, fatigue, respiratory status and ALSFRSAmyotrophic Lateral Sclerosis20089526627218608103
- DroryVEGrossDNo effect of creatine on respiratory distress in amyotrophic lateral sclerosisAmyotroph Lateral Scler Other Motor Neuron Disord200231434612061948
- PastulaDMMooreDHBedlackRSCreatine for amyotrophic lateral sclerosis/motor neuron diseaseCochrane Database Syst Rev201212CD00522523235621
- KulieTGroffARedmerJHounshellJSchragerSVitamin D: an evidence-based reviewJ Am Board Fam Med200922669870619897699
- GianforcaroASolomonJAHamadehMJVitamin D(3) at 50× AI attenuates the decline in paw grip endurance, but not disease outcomes, in the G93A mouse model of ALS, and is toxic in femalesPLoS One201382e3024323405058
- GianforcaroAHamadehMJDietary vitamin D3 supplementation at 10x the adequate intake improves functional capacity in the G93A transgenic mouse model of ALS, a pilot studyCNS Neurosci Ther201218754755722591278
- CamuWTremblierBPlassotCVitamin D confers protection to motoneurons and is a prognostic factor of amyotrophic lateral sclerosisNeurobiol Aging20143551198120524378089
- KaramCBarrettMJImperatoTMacGowanDJScelsaSVitamin D deficiency and its supplementation in patients with amyotrophic lateral sclerosisJ Clin Neurosci201320111550155323815870
- McCordJMThe evolution of free radicals and oxidative stressAm J Med2000108865265910856414
- D’AmicoEFactor-LitvakPSantellaRMMitsumotoHClinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosisFree Radic Biol Med20136550952723797033
- OrrellRWLaneRJRossMA systematic review of antioxidant treatment for amyotrophic lateral sclerosis/motor neuron diseaseAmyotroph Lateral Scler20089419521118608090
- OrrellRWLaneRJRossMAntioxidant treatment for amyotrophic lateral sclerosis / motor neuron diseaseCochrane Database Syst Rev20071CD00282917253482
- ReynoldsEVitamin B12, folic acid, and the nervous systemLancet Neurol200651194996017052662
- WatanabeFVitamin B12 sources and bioavailabilityExp Biol Med (Maywood)2007232101266127417959839
- KajiRKodamaMImamuraAEffect of ultrahigh-dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: a double-blind controlled studyMuscle Nerve19982112177517789843082
- KajiRKuzuharaSIwasakiYUltra-high dose methylcobalamin (E0302) prolongs survival of ALS: report of 7 years’ randomised double-blind, phase 3 clinical trial (ClinicalTrials.gov NCT00444613)Paper presented at: AAN Annual Meeting2015
- ALS-UntangledALSUntangled No. 30: methylcobalaminAmyotroph Lateral Scler Frontotemporal Degener2015167–853653926203660
- GulcinIAntioxidant and antiradical activities of L-carnitineLife Sci200678880381116253281
- BeghiEPupilloEBonitoVRandomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALSAmyotroph Lateral Scler Frontotemporal Degener2013145–639740523421600
- TurunenMOlssonJDallnerGMetabolism and function of coenzyme QBiochim Biophys Acta200416601–217119914757233
- FerranteKLShefnerJZhangHTolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALSNeurology200565111834183616344537
- KaufmannPThompsonJLLevyGPhase II trial of CoQ10 for ALS finds insufficient evidence to justify phase IIIAnn Neurol200966223524419743457
- KelsoGFPorteousCMCoulterCVSelective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic propertiesJ Biol Chem200127674588459611092892
- MiquelECassinaAMartinez-PalmaLNeuroprotective effects of the mitochondria-targeted antioxidant MitoQ in a model of inherited amyotrophic lateral sclerosisFree Radic Biol Med20147020421324582549
- SnowBJRolfeFLLockhartMMProtect Study GroupA double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson’s diseaseMov Disord201025111670167420568096
- WatanabeTTaharaMTodoSThe novel antioxidant edaravone: from bench to bedsideCardiovasc Ther200826210111418485133
- AokiMWaritaHMizunoHSuzukiNYukiSItoyamaYFeasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavengerBrain Res2011138232132521276427
- ItoHWateRZhangJTreatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS miceExp Neurol2008213244845518718468
- AbeKItoyamaYSobueGConfirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patientsAmyotroph Lateral Scler Frontotemporal Degener2014157–861061725286015
- TanakaMSakataTPalumboJAkimotoMA 24-week, phase III, double-blind, parallel-group study of edaravone (MCI-186) for treatment of amyotrophic lateral sclerosis (ALS)Paper presented at: AAN Annual Meeting2016Vancouver, Canada
- PetrovDMansfieldCMoussyAHermineOALS clinical trials review: 20 years of failure. are we any closer to registering a new treatment?Front Aging Neurosci201796828382000